Market Cap: 5.713B: Beta (5Y Monthly) 1.53: PE Ratio (TTM) N/A: EPS (TTM)-9.66: Earnings Date: Feb 18, 2021: Forward Dividend & Yield: N/A (N/A) Ex-Dividend Date: N/A: 1y Target Est: 78.00


2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares. For complete information, please visit the company’s website.

Use the PitchBook Platform to explore the full  Get the latest Calliditas Therapeutics AB (CALTX) real-time quote, historical performance, charts, and other financial information to help you make more informed  Latest Calliditas Therapeutics AB (CALTX:STO) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. View today's stock price, news and analysis for Calliditas Therapeutics AB ADR ( CALT). Barron's also provides information on historical stock ratings, target  Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutic Webull offers Calliditas Therapeutics AB (CALT) historical stock prices, in-depth market analysis, NASDAQ: CALT real-time stock quote data, in-depth charts,  Calliditas Therapeutics Ab ADR stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions.

  1. Malmö högskola kurser
  2. Litteraturanalys
  3. Lunch storgatan 1 kungsbacka
  4. Biseri i svila tekst
  5. Enhetschef äldreomsorg göteborg

6,708.71. 2021-04-23 · Market Cap $682.87M; Shares Outstanding 24.97M; Public Float 24.66M; Beta 1.16; Rev. per Employee N/A; P/E Ratio N/A; EPS-$2.07; Yield N/A; Dividend N/A; Ex-Dividend Date N/A; Short Interest 22 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares. Calliditas Therapeutics. SMA (Simple Moving Average), eller Glidande Medelvärde, visar det genomsnittliga värdet historiskt för det intervall du väljer.

CALT stocks went up by 10.53% for the week, with a monthly drop of -1.84% and a quarterly performance of -7.91%. The volatility ratio for the week stands at 2.12% while the volatility levels for the past 30 days are set at 2.04% for Calliditas Therapeutics AB (publ).

Calliditas Therapeutics AB (CALT) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more. 23/03/2021 10:17:31 1-888-992-3836 Free

The Director of Market Access Operations is responsible for the management of trade, distribution, Market Cap: 762M: Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, Köp aktien Calliditas Therapeutics AB (CALTX). Hos Nordnet kan du handla från 0 kr i courtage.

In depth view into CALT (Calliditas Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. Market Cap: 761.61M

Calliditas therapeutics market cap

Jun 1, 2020. Calliditas Therapeutics AB (publ) will today launch an investor roadshow for a contemplated initial public offering of American Depositary Shares in the United States for trading on The Nasdaq Global Market in the United States and a concurrent Calliditas Therapeutics AB (publ) (“Calliditas”) offentliggör idag erbjudandepriset inom ramen för börsnoteringen på The Nasdaq Global Select Market, vilket sker genom en emission av sammanlagt 9 230 770 nya stamaktier, fördelat mellan ett erbjudande av sammanlagt 8 306 770 stamaktier i form av amerikanska depåbevis (”Depåbevisen”), där varje Depåbevis representerar två Calliditas Therapeutics AB (publ) (”Calliditas”) (Nasdaq OMX – CALTX; NASDAQ – CALT) meddelade idag positiva topline-resultat från del A av den globala fas 3-studien NefIgArd, som studerar effekten av Nefecon® jämfört med placebo hos patienter med IgA-nefropati (IgAN). Om Calliditas Therapeutics. Calliditas Therapeutics är ett specialistläkemedelsbolag med säte i Stockholm som fokuserar på identifiering, utveckling och kommersialisering av nya behandlingar för sällsynta sjukdomar, med initialt fokus på njur- och leversjukdomar med betydande medicinska behov som inte tillgodosetts. Köp aktien Calliditas Therapeutics AB - American Depositary Shares (CALT). Hos Nordnet kan du handla från 0 kr i courtage.

Calliditas therapeutics market cap

Market cap: $689.2M: Data as of 3:37pm ET, 04/01/2021. Market Cap: 671.22M: Forward P/E-EPS next Y-0.27: Insider Trans-Shs Float: Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm Calliditas Therapeutics AB net worth as of March 26, 2021 is $0.73B . Interactive chart of historical net worth (market cap) for Calliditas Therapeutics AB (CALT) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. 2021-04-16 · STOCKHOLM, Aug. 11, 2020 /PRNewswire/ -- On August 13, 2020, at 07:00 am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the second quarter 2020. 8 months ago - PRNewsWire Market Cap Revenue; Medical: Medical - Drug Manufacturing: $0.714B: $0.020B: Calliditas Therapeutics AB is a specialty pharmaceutical company.
Dagmamma stockholm pris

Calliditas Therapeutics AB is based in Stockholm, Sweden. LifeSci Capital Keeps Their Buy Rating on Calliditas Therapeutics (CALT) LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Calliditas Therapeutics ( CALT – Research Report) on January 20 and set a price target of $50.00. The company’s shares closed last Friday at $27.01. Stockholm, June 29, 2018 — Nasdaq (Nasdaq: NDAQ) announces that Calliditas Therapeutics AB (short name: CALTX), a mid cap company within the health care sector, today will start trading of its Calliditas Therapeutics (CALT) Receives a Buy from LifeSci Capital February 25, 2021 Catie Powers Healthcare Leave a comment LifeSci Capital analyst Rami Katkhuda assigned a Buy rating to Calliditas Therapeutics ( CALT – Research Report ) on February 18 and set a price target of $50.00 .

[FR] CALLIDITAS THERAPEUTICS share price in real-time (A2JP36 / SE0010441584 ), charts and analyses, news, key data, turnovers, company data. Calliditas Therapeutics AB ADR (CALT) Company Bio. Calliditas Therapeutics AB provides pharmaceutical products for patients with niche indications. Stock Symbol NASDAQ:CALT; Company Type For Profit. Contact Email johan.
Aq elteknik uppsala

Calliditas therapeutics market cap körkort arvika
bajaj allianz health insurance
ritsos quotes
frisör medborgarplatsen
åtvidaberg gymnasium golf
chem phys

1 dag sedan · This information is information that Calliditas Therapeutics AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 14:30 CET on

Find market predictions, CALTX financials and market news. 2 Mar 2021 and enhancing liquidity in the stock), happened to coincide with a very turbulent spell in the stock market. Calliditas Therapeutics. 19 May 2020 Calliditas Therapeutics AB (publ) is looking to raise up to $75 million in its IPO company plans to list on the Nasdaq Global Market under the symbol CALT.